HIGHLIGHTS
- who: Koichi Ando and collaborators from the Division of Respirology and Allergology, Department of Medicine, Showa University School of Medicine, Hatanodai, Shinagawa-ku, Tokyo, Japan have published the research: Comparative Efficacy of ALK Inhibitors for Treatment-Nau00efve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis, in the Journal: (JOURNAL)
- what: The aim of this systematic review was to verify all publicized phase III clinical trials to make comparisons and rank the efficacy of the seven therapeutic groups in terms of efficacy; namely, ensartinib, lorlatinib, brigatinib, alectinib . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.